- Revenue: $106.8 million, up 17% YoY; QoQ growth around 4.6% (Q2 2025 was $102.1 million).
- Gross profit: $72.263 million; gross margin ~67.66%, up from prior-year levels (~66.2%).
- Operating loss: $(13.84) million; operating margin ≈ −12.96%.
- EBITDA: $(6.27) million; EBITDA margin ≈ −5.87% for the quarter; adjusted EBITDA: $9.8 million; adjusted EBITDA margin: 9%.
- Net income: $(14.40) million; net margin ≈ −13.49%.
- Earnings per share (GAAP): Not explicitly reconciled in the GAAP table; reported EPS (non-GAAP) shown as 0.65 in the data, which appears inconsistent with a GAAP loss; weighted average diluted shares ≈ 57.9 million.
- AHSCs (Average Healthcare Services Clients): 4,200 for FY2025; growth of 68 AHSCs quarter-over-quarter; total revenue per AHSC: $25,207, up 1% YoY and 3% QoQ.
- Revenue per AHSC trend: +1% YoY, +3% QoQ; indicates selective pricing/upsell in a higher-value mix.
- Cash flow: Operating cash flow +$5.8 million; Free cash flow +$1.6 million (positive for second consecutive quarter).
- Balance sheet:
- Cash and equivalents: ~$81.7 million; Net cash position: ~$70.6 million (net debt negative).
- Total assets: ~$375.7 million; Total liabilities: ~$121.1 million; Total stockholders’ equity: ~$254.6 million.
- Debt: Total debt ≈ $11.1 million; no borrowings on the $50 million facility.
- Guidance (FY2025): Revenue $418–$420 million; Adjusted EBITDA $34–$36 million; AHSC ~4,200; Revenue per AHSC growth expected vs FY2024.
- Guidance (FY2026): Revenue $472–$482 million; Adjusted EBITDA $78–$88 million; AHSC ~4,500; assumption of no additional acquisitions through Jan 31, 2026; continued rise in revenue per AHSC expected.
- Management tone: Emphasized expense discipline, reinvestment where it drives growth, and a pipeline of new solutions and integrations.
- Transcript cues: Management highlighted ongoing network expansion, higher adoption, and the potential of new offerings, while also noting the wind-down of a clearinghouse client in FY2024 that affected growth rates.